The cash price of brand tirzepatide is roughly $1,300 per month for Zepbound\u00ae and $1,100 per month for Mounjaro\u00ae without insurance. Compounded tirzepatide from a 503A or 503B pharmacy typically runs $250 to $500 per month, slightly higher than compounded semaglutide due to higher API cost. Insurance coverage varies by indication and plan.<\/p>\n
This article breaks down each price point, the drivers behind them, insurance approval mechanics, and realistic savings strategies. Eli Lilly’s manufacturer programs, employer carve-outs, telehealth compounding, and direct-to-patient channels each have different prices for the same molecule.<\/p>\n
Pricing has shifted multiple times since tirzepatide came off the FDA shortage list in late 2024 and subsequent enforcement actions affected the compounding landscape. Current numbers reflect the situation as of early 2026.<\/p>\n
At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.<\/p>\n
Zepbound’s list price is $1,349 per month in 2026.<\/strong> Mounjaro’s list price is $1,135 per month. Real retail prices at pharmacies often run higher due to markups: $1,500 to $1,700 for Zepbound is common, and Mounjaro frequently runs $1,100 to $1,300 cash.<\/p>\n Quick Answer: Brand Zepbound cash price: $1,300\/month list, often $1,500+ at retail<\/p>\n Eli Lilly introduced LillyDirect in 2024, a direct-to-patient channel for Zepbound vials (not pens) at $399 to $549 per month depending on dose. The lower price reflects bypassing pharmacy and PBM markups. The vials require self-administration with separately purchased syringes.<\/p>\n Cash-pay patients without LillyDirect access often use GoodRx, SingleCare, or pharmacy-specific coupons to shave 10 to 20% off list. Discounts are modest because PBMs negotiate most of the actual price reduction through rebates that don’t reach uninsured patients.<\/p>\n Compounded tirzepatide pricing has fluctuated significantly.<\/strong> During the FDA shortage period (2022 to 2024), prices ran $300 to $600 per month at telehealth services. After the shortage resolved and FDA restrictions tightened on compounding, the landscape changed.<\/p>\n As of 2026, typical compounded tirzepatide pricing through legitimate telehealth platforms runs:<\/p>\n The price gradient reflects the actual amount of API per dose. Higher milligram doses cost more in raw material.<\/p>\n TrimRx works with FDA-registered 503B outsourcing facilities and offers transparent pricing with no hidden charges. The free assessment quiz determines eligibility before any payment is required.<\/p>\n Commercial insurance coverage for tirzepatide depends heavily on indication.<\/strong> Mounjaro coverage for type 2 diabetes is widely available with prior authorization. Zepbound coverage for weight loss is more restricted.<\/p>\n A 2024 Mercer survey found about 47% of large employers cover GLP-1 drugs for obesity, including tirzepatide. Coverage requirements typically include BMI over 30, or BMI over 27 with comorbidities like type 2 diabetes, hypertension, or sleep apnea. Documented prior weight loss attempts are often required.<\/p>\n Step therapy is common. Some plans require trying semaglutide (or other GLP-1 drugs) before approving tirzepatide due to formulary preferences. Some plans require ongoing weight loss documentation (typically 5% loss at 6 months) to continue coverage.<\/p>\n Medicare Part D covers Mounjaro for type 2 diabetes.<\/strong> Mounjaro is also covered for obstructive sleep apnea in obesity following the December 2024 FDA approval based on SURMOUNT-OSA.<\/p>\n Medicare does not cover tirzepatide for weight loss alone. Federal law (the Medicare Modernization Act of 2003) prohibits coverage of drugs for weight loss. The OSA indication created a new path for Medicare-covered tirzepatide use in patients with documented OSA.<\/p>\n Medicare beneficiaries who want tirzepatide for weight loss alone without a covered indication are in the cash-pay market, where LillyDirect, compounded options, or manufacturer assistance programs are typically the only affordable routes.<\/p>\n Medicaid coverage varies by state.<\/strong> As of 2026, about 13 states cover Zepbound for weight loss with prior authorization. Most states cover Mounjaro for diabetes. The patchwork makes coverage state-specific and subject to change with state budgets.<\/p>\n For Medicaid patients without diabetes or OSA, compounded tirzepatide may be more affordable than out-of-pocket brand, though some states restrict patients from using telehealth compounding while enrolled in Medicaid.<\/p>\n State Medicaid pharmacy benefit pages or pharmacy assistance lines clarify current coverage. Coverage rules often change between fiscal years.<\/p>\n Eli Lilly offers a Zepbound savings card for commercial insurance patients that can bring out-of-pocket costs to as low as $25 per month, capped at $150 to $200 in some cases.<\/strong> The card has annual maximum savings and isn’t available to Medicare, Medicaid, TRICARE, or VA patients.<\/p>\n The Mounjaro savings card structure is similar, with caps and exclusions. Both cards require coverage of the medication by the patient’s primary insurance, just at high out-of-pocket cost. They don’t fill gaps for plans that exclude the drug.<\/p>\n LillyDirect’s vial program at $399 to $549 per month is a separate offering for patients without coverage. This represents a direct manufacturer-to-patient channel at a price well below traditional retail.<\/p>\n A separate Lilly Cares Patient Assistance Program offers free medication for patients without insurance who meet income criteria (typically under 400% of federal poverty level). Application requires income documentation and physician sign-off.<\/p>\n For most uninsured or underinsured patients, compounded tirzepatide is significantly cheaper than brand pens, though more expensive than LillyDirect vials.<\/strong> A patient at full maintenance dose typically pays $400 to $500 per month compounded vs $1,300+ for Zepbound pens or $549 for LillyDirect vials.<\/p>\n The price difference reflects several factors: compounding pharmacies don’t carry the same regulatory burden as a new drug application, they source API directly from FDA-registered manufacturers, they don’t pay PBM rebates or wholesaler markups, and they don’t carry marketing costs.<\/p>\n Compounded tirzepatide isn’t FDA-approved as a specific finished product, but the pharmacies that prepare it are state-licensed (503A) or FDA-registered (503B) and operate under USP 797 sterility standards.<\/p>\n LillyDirect Zepbound vials at $399 to $549 per month represent a major price disruption.<\/strong> For many patients without insurance, the brand vial at this price competes directly with compounded options.<\/p>\n Trade-offs to consider:<\/p>\n For patients at higher doses (10 to 15 mg), LillyDirect may be cheaper than some compounded options. For patients at lower doses, compounded is usually cheaper. Personal preference and specific telehealth service pricing determine which option fits.<\/p>\n Key Takeaway: Compounded tirzepatide via telehealth: $250 to $500\/month<\/p>\n Telehealth GLP-1 services typically bundle the medical visit, prescription, and medication delivery into a monthly subscription.<\/strong> Common structures include flat monthly subscription with medication included, subscription plus dose-based medication pricing, pay-as-you-go pricing per shipment, and quarterly or annual prepay discounts.<\/p>\n TrimRx provides a personalized treatment plan with transparent monthly pricing that includes provider consultations, medication, and shipping. There are no hidden activation fees or surprise charges.<\/p>\n Cancellation policies and refund terms vary significantly between platforms. Reading the terms before signing up is worth the few minutes.<\/p>\n Both health savings accounts (HSAs) and flexible spending accounts (FSAs) can be used for tirzepatide when prescribed for an FDA-approved indication.<\/strong> For Mounjaro and Zepbound, that includes type 2 diabetes, weight loss with BMI criteria, and obstructive sleep apnea in obesity.<\/p>\n For compounded tirzepatide, HSA\/FSA eligibility is generally allowed as long as it’s prescribed by a licensed clinician for a medical purpose. Some HSA administrators may require additional documentation.<\/p>\n The pre-tax benefit makes a substantial difference. A patient in the 24% federal tax bracket effectively saves 24% off the cash cost by paying through HSA or FSA dollars.<\/p>\n Tirzepatide is a chronic-disease medication.<\/strong> Stopping after the initial loss phase typically leads to regain. The relevant question for cost planning is annual cost over 5 or 10 years, not just the loss phase.<\/p>\n At brand pricing with no coverage, that’s $15,000 to $20,000 per year. At LillyDirect pricing, $4,800 to $6,600 per year. At compounded pricing, $3,000 to $6,000 per year. Even with insurance copays, brand can run $1,000 to $3,000 per year out-of-pocket.<\/p>\n Some clinicians use lower maintenance doses (5 or 7.5 mg) after the active loss phase to reduce ongoing cost. There’s no head-to-head trial of maintenance levels, but observational data support this approach for many patients.<\/p>\n Brand pricing is similar between tirzepatide and semaglutide: roughly $1,000 to $1,300 per month list.<\/strong> Compounded tirzepatide tends to run slightly higher than compounded semaglutide ($300 to $500 vs $150 to $400) due to higher API cost.<\/p>\n LillyDirect’s $399 to $549 vial program for Zepbound has no direct equivalent for semaglutide. Novo Nordisk has not introduced a similar direct channel as of 2026.<\/p>\n Patients choosing between the drugs often consider clinical factors first (efficacy, side effects, comorbidities) and cost second. The 5 to 6 percentage point efficacy advantage of tirzepatide in obesity trials sometimes justifies the slightly higher compounded cost.<\/p>\n GLP-1 drug pricing in the US has been politically controversial.<\/strong> Multiple senators have called for price reductions. The Inflation Reduction Act’s drug price negotiation provisions could affect Medicare-covered tirzepatide pricing starting in 2027 or 2028, depending on when the drug is selected for negotiation.<\/p>\n Eli Lilly has signaled some willingness to introduce more affordable options. LillyDirect’s $399 vial program represents one such move. Whether additional direct-to-patient pricing or institutional discounts will emerge is being watched.<\/p>\n Compounded pricing depends on FDA enforcement decisions and 503A\/503B regulatory developments. Court challenges to FDA decisions about tirzepatide compounding could affect availability and pricing through 2026 and 2027.<\/p>\n Beyond the medication itself, patients incur supplemental costs for:<\/p>\n These add roughly $50 to $150 per month to the total cost of treatment for most patients. Some telehealth services bundle most supplies into the subscription price. Others charge separately.<\/p>\n Bottom line: Medicare cannot legally cover weight-loss drugs as of 2026<\/p>\n The active molecule is identical. Clinical effect should be the same when dosed equivalently. Differences are regulatory (compounded isn’t FDA-approved as a finished product) and in inactive ingredients. Compounded pharmacies sourcing API from FDA-registered manufacturers produce a chemically equivalent product.<\/p>\n LillyDirect bypasses the traditional pharmacy distribution chain and PBM rebate system. Eli Lilly sells directly to patients without wholesaler and retail pharmacy markups. The vial format (rather than pen) also costs less to manufacture.<\/p>\n Yes. The active molecule is the same. The vial requires drawing the dose into a syringe rather than using a fixed-dose pen. Some patients find vials more flexible because they can fine-tune doses or split doses.<\/p>\n Sometimes. Coverage depends on the plan, the indication submitted, and any step therapy requirements. Prediabetes with elevated BMI may qualify under Zepbound’s obesity indication on plans that cover it. Pure prediabetes without weight criteria is often not enough for approval.<\/p>\n Yes, with commercial insurance. The card lowers the patient’s copay after insurance has been billed. It doesn’t work alongside Medicare, Medicaid, TRICARE, or VA benefits due to federal anti-kickback regulations.<\/p>\n Tirzepatide brand pricing is comparable to semaglutide brand pricing. Compounded tirzepatide tends to run $100 to $150 more per month than compounded semaglutide at equivalent maintenance doses. LillyDirect provides a unique mid-tier pricing option for tirzepatide that has no semaglutide equivalent.<\/p>\n Compounded tirzepatide or LillyDirect vials are common bridges for patients who lose insurance mid-treatment. Manufacturer patient assistance programs are another option for income-qualified patients. Stopping abruptly typically leads to regain over the following 6 to 12 months, so finding a backup is worth the effort.<\/p>\n Disclaimer:<\/strong> This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.<\/p>\n","protected":false},"excerpt":{"rendered":" The cash price of brand tirzepatide is roughly $1,300 per month for Zepbound and $1,100 per month for Mounjaro without insurance.<\/p>\n","protected":false},"author":11,"featured_media":90792,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"_yoast_wpseo_title":"Tirzepatide Cost Breakdown: Brand, Compounded, Insurance & Savings Options","_yoast_wpseo_metadesc":"The cash price of brand tirzepatide is roughly $1,300 per month for Zepbound and $1,100 per month for Mounjaro without insurance.","_yoast_wpseo_focuskw":"tirzepatide cost breakdown","footnotes":"","_flyrank_wpseo_metadesc":""},"categories":[11],"tags":[],"class_list":["post-90793","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-mounjaro"],"_links":{"self":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90793","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/comments?post=90793"}],"version-history":[{"count":3,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90793\/revisions"}],"predecessor-version":[{"id":92554,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/posts\/90793\/revisions\/92554"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media\/90792"}],"wp:attachment":[{"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/media?parent=90793"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/categories?post=90793"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/trimrx.com\/blog\/wp-json\/wp\/v2\/tags?post=90793"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}What Does Compounded Tirzepatide Cost?<\/h2>\n
\n
What Does Insurance Cover?<\/h2>\n
Does Medicare Cover Tirzepatide?<\/h2>\n
What Does Medicaid Cover?<\/h2>\n
What Are the Manufacturer Savings Programs?<\/h2>\n
How Does Compounded Compare on Cost?<\/h2>\n
What About LillyDirect vs Compounded?<\/h2>\n
\n
How Do Telehealth Platforms Structure Pricing?<\/h2>\n
Are HSAs and FSAs Eligible?<\/h2>\n
What’s the Cost of Staying on Long-term?<\/h2>\n
Cost Comparison with Semaglutide<\/h2>\n
What’s the Future Pricing Trajectory?<\/h2>\n
How Do Supplemental Costs Affect Overall Budget?<\/h2>\n
\n
FAQ<\/h2>\n
Is Compounded Tirzepatide as Effective as Zepbound?<\/h3>\n
Why Is LillyDirect Cheaper Than Retail?<\/h3>\n
Can I Switch Between Brand Pens and LillyDirect Vials?<\/h3>\n
Will Insurance Cover Tirzepatide for Prediabetes?<\/h3>\n
Does the Manufacturer Savings Card Stack with Insurance?<\/h3>\n
How Does Pricing Compare to Semaglutide?<\/h3>\n
What If I Lose Insurance Coverage Mid-treatment?<\/h3>\n